Journey Medical Corporation (DERM) Reports Q2 Loss, Beats Revenue Estimates
Journey Medical (DERM) delivered earnings and revenue surprises of -128.57% and +1.11%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?